98%
921
2 minutes
20
A modified enzyme-linked immunosorbent assay (ELISA) with nanomaterials is an effective and powerful method to amplify the signal and reduce the cost of detecting and measuring trace biomarkers or proteins. In this study, an ultra-sensitive colorimetric immunoassay was designed, and its ability to detect influenza viruses using positively charged gold nanoparticles ((+)Au NPs) was assessed as a possible role for peroxidase-mimic inorganic enzymes. This method detected influenza virus A (H1N1) with a linear range up to 10 pg mL(-1) and clinically isolated influenza virus A (H3N2) up to 10 plaque forming units (PFU) mL(-1) , where its sensitivity improved to 500-fold higher than that of commercial virus kits. The sensitivity of this proposed method was not declined even though in complex biological media in compared to conventional ELISA. These results revealed that the (+)AuNP-based colorimetric immunoassay could be suitable for lab-on-a-chip device and open new opportunities for clinical protein diagnostics. Biotechnol. Bioeng. 2016;113: 2298-2303. © 2016 Wiley Periodicals, Inc.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bit.25982 | DOI Listing |
Elife
September 2025
Chinese Academy of Medical Science Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Influenza virus neuraminidase (NA) is a crucial target for protective antibodies, yet the development of recombinant NA protein as a vaccine has been held back by instability and variable expression. We have taken a pragmatic approach to improving expression and stability of NA by grafting antigenic surface loops from low-expressing NA proteins onto the scaffold of high-expressing counterparts. The resulting hybrid proteins retained the antigenic properties of the loop donor while benefiting from the high-yield expression, stability, and tetrameric structure of the loop recipient.
View Article and Find Full Text PDFClin Lab
September 2025
Background: Patients with epilepsy often require long-term antiepileptic medications, which can affect hematological parameters. Influenza (H1N1) infection is known to potentially cause thrombocytopenia. This case examines the clinical implications of a 29-year-old female patient with epilepsy who developed influenza and significant platelet reduction.
View Article and Find Full Text PDFTher Adv Respir Dis
September 2025
Department of Respiratory Medicine, Shangyu People's Hospital of Shaoxing, Zhejiang, China.
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition associated with increased morbidity and mortality, particularly during respiratory infections such as influenza. The interaction between COPD and influenza is multifaceted, involving compromised immune responses, chronic inflammation, and impaired lung function. Influenza infection can exacerbate COPD, leading to acute exacerbations, hospitalizations, and higher mortality.
View Article and Find Full Text PDFLab Chip
September 2025
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215, USA.
CRISPR technology offers an entirely new approach to therapeutic development because it can target specific nucleotide sequences with high specificity, however, preclinical animal models are not useful for evaluation of their efficacy and potential off-target effects because of high gene sequence variations between animals and humans. Here, we explored the potential of using the CRISPR effector Cas13 to develop a new therapeutic approach for influenza A virus (IAV) infections based on its ability to specifically and robustly cleave single-strand viral RNA using a complementary CRISPR RNA (crRNA). We engineered crRNAs to target highly conserved regions in the IAV genome to create a potential pan-viral treatment strategy.
View Article and Find Full Text PDFInfect Drug Resist
September 2025
Department of Infectious Diseases, Ningbo No.2 Hospital, Ningbo, 315010, People's Republic of China.
Objective: Multiple studies have confirmed that viral pneumonia is a high-risk factor for invasive pulmonary aspergillosis (IPA), this retrospective study aims to analyze the differences in clinical characteristics, prognosis, and high-risk factors for mortality between patients with influenza virus-associated pulmonary aspergillosis (IAPA) and those with COVID-19-associated pulmonary aspergillosis (CAPA).
Methods: Clinical data from IAPA and CAPA patients diagnosed at four hospitals were collected. The clinical characteristics and prognostic differences between the two groups were analyzed and compared, with Cox regression used to identify the risk factors for mortality.